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Oral polio vaccine (OPV) proved to be superior in administration eliminating the need of sterile 
syringes and making the vaccine more suitable for mass vaccination campaigns. Poliovirus is heat 
sensitive in nature, and thus OPV is stored at low temperature (frozen). The growth medium containing 
varying concentration of serum such as 6, 8, 10, 12, 14% were prepared. 10 ml of the above mentioned 
growth media containing different concentration of serum were added to different culture bottles. The 
culture flasks containing different volumes of growth medium with 10% serum concentration such as 8, 
9, 10, 11 and 12 ml were added to a series of culture flasks. All the culture flasks were inoculated with 
the RD cells (10,000 cells/culture flask) and kept at 37°C. The most favoured serum concentration and 
volume for the growth of RD cells was found and used for testing the potency of vaccine. Vaccines 
from two manufacturers were kept at three different temperatures, 2-8 ± 0.5°C (refrigerator), 26 ± 0.5°C 
and 37 ± 0.5°C (Incubator). Cytopathic viruses were titrated by the determination of a tissue culture 
infectious dose50 (TCID50), vaccine dilutions were seeded in replicate onto cells in multiwell plates 
(usually 96 wells). After a suitable incubation period, wells were examined microscopically and scored 
as infected or not infected. The potency of vaccines was tested using the Karber’s Formula. 
 





Poliomyelitis, often called polio or infantile paralysis, is an 
acute viral infectious disease spread from person to 
person, primarily via the faecal-oral route. Although effec-
tive poliovirus vaccines have been available for over a 
quarter of a century, paralytic poliomyelitis remains a 
serious health risk in many countries. In developing 
countries the incidence of the disease remains high. 
Even though concerted vaccination campaigns have im-
proved the situation in certain regions, more urgent 
health priorities or difficulties arising from poor economies 
or political uncertainty, have meant that vaccination 
against poliomyelitis worldwide has not been sufficiently 
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global incidence of the disease. Even in developed 
countries, poliomyelitis, although greatly diminished in 
incidence, has not disappeared. Continuing circulation of 
wild-type strains and regular importation of virus from the 
third world necessitates continued vigilance in 
maintaining high levels of immunity. Although developed 
countries generally experienced a dramatic decrease in 
poliomyelitis after vaccination was introduced, those 
countries using the live-attenuated vaccines developed 
by Albert Bruce Sabin have noted a residual low level of 
approximately 0.02 - 0.2 cases/million of population/ 
years. Evidence has accumulated that this persistent low 
level of disease may be caused by the vaccines 
themselves, especially those of serotypes 2 and 3. 
Polioviruses are members of the Enterovirus genus of 
the family Picornaviridae. The three distinct serotypes 1, 
2 and 3 cause identical disease and are very similar in 






diameter icosahedral capsid consists of 60 copies each 
of four virus polypeptides, VP1-VP4, surrounding a single 
stranded, messenger-sense RNA genome of approxi-
mately 7450 nucleotides (Almond et al., 1984). 
Most vaccines, live vaccines particularly, are tempe-
rature sensitive. To ensure an adequate shelf life, they 
should be kept at a low temperature. Consequently, their 
delivery requires the provision of a cold chain. The least 
stable of the common childhood vaccines is the live 
attenuated polio vaccine (OPV). It is a non-freeze-dried 
vaccine and is composed of a single attenuated strain of 
each of the three serotypes (Rombaut et al., 1996). 
Thermostability requirements were defined by the 
WHO that, fall in titre value for the three vaccine strains 
after exposure to 37°C for two days should be less than 
0.5 log10 of titre. In addition current regulations require 
that, for maintenance of potency, the vaccine must be 
stored and shipped frozen and that, after thawing, it must 
be held in the refrigerator at no more than 10°C for a 
period not to exceed 30 days, after which time it must be 
discarded (Rombaut et al., 1996), the ideal preparation 
should deliver the antigen in such a way that a long 
lasting effect is achieved and provides protection. The 
studies have been undertaken to study the stability of 
OPV at different temperatures and the effect of varying 
serum concentrations and volume on the medium used to 
grow the RD cells that are utilized for the potency test 
and to measure the tolerance of the OPV to higher tem-
perature, thus creating an awareness for the importance 
of cold chain maintenance. 
 
 
MATERIALS AND METHODS 
 
Revival of cells 
 
The liquid nitrogen storage register was checked and the cell seeds 
to be revived were selected. The vials were transferred immediately 
to a beaker of water maintained at 36°C. The contents were thawed 
completely, the vials were wiped from outside with alcohol to reduce 
bacterial contamination. 1 ml of 10% Growth Medium was added 
drop by drop and shook gently after each addition. The contents 
were transferred into 10ml of the growth medium in a culture bottle 
drop by drop. The culture bottle was incubated at 36°C for 5 - 6 h till 
the cells adhered. If the cells had adhered during this period it was 
replaced with fresh GM, otherwise the bottle was incubated at 36°C 
overnight. After ensuring the confluent monolayer formation, the 
cells were sub-cultured. 
 
 
Cell splitting  
 
The culture flasks (25 cm2) were examined for confluent monolayer 
of RD cell lines for Quality and absence of contamination. The 
growth medium was decanted from the cell culture flasks and gently 
washed the confluent monolayer with 3 ml incomplete PBS twice. 3 
ml of trypsin was added to the monolayer and dispersed evenly. 
Trypsin was decanted off the flasks and left until streaks appeared 
at the edges. The flask was tapped few times against the hand to 
detach all the cells. The cells were re-suspended in 5 ml growth 
medium, which neutralize the action of trypsin. The suspension was 
gently aspirated few times with a pipette  to  break  up  cell  clumps.  




The cell count was performed and diluted in 10% growth medium.  
After seeding of cells, the fresh culture flasks were capped tightly 
and placed in a 36°C incubator. The growth medium (10%) in the 
culture flask was changed to maintenance medium (2%) after a 





The monolayer cell culture was trypsinized. To each well of the 96 
well microtitre plates 0.1ml of the cell suspension containing 
approximately 10,000 cells were added. The plates were then 
incubated at 37°C for one day in 5% CO2 atmosphere. The medium 
from all the wells were removed by flicking. The trypsin was added 
to all the wells (0.1 ml/well). The plates were incubated at 37°C for 
3 - 5 min, and then 1 ml of medium was added to all the wells. The 
wells were dispersed and cell suspension was pooled from the 
wells to eppendorf tubes. Equal amount of tryphan blue dye was 
added and cell count was done using Haemocytometer. Discarded 
and re-suspended the original cell suspension if cell clumping was 
observed. The mean count of the cells was calculated.  
 
The cell concentration/ml was calculated using the following 
formula 
 
C1 = m x tb x 104 
 
Where m = Mean of the cell count of the 4 corners, tb = correction 
to the tryphan blue dilution, and C1 = Initial cell concentration/ml. 
Depending on the count, the cells were seeded into bottles and 





The normal serum concentration in GM is 10%. The effects of vary-
ing serum concentrations of 6, 8, 10, 12 and 14% on the growth of 
RD cells used for the potency test were studied. The best concen-
tration of the serum in which the maximum cell growth achieved 
was selected to be the optimum concentration of serum. 
 
 
Volume of media 
 
The Rhabdomyosarcoma cells used for the potency test were 
grown in different volumes of growth medium containing 10% 
serum, different volumes of growth media such as 8, 9, 10, 11 and 
12 ml were selected for the study. The best volume of serum that 
helps in the growth of RD cells was found out by the study. 
 
 
Estimation of potency for vaccines kept at 2-8 ± 0.5°C, 26 ± 
0.5°C and 37 ± 0.5°C 
 
RD culture bottle with confluent monolayer was selected. Cells not 
more than 2 days old were taken. The medium was discarded. The 
cells were trypsinized, counted and seeded accordingly. Three 
different sterile microtitre plates were chosen for the titration of 
vaccines kept at 2-8 ± 0.5°C (refrigerator), 26 ± 0.5°C and 37 ± 
0.5°C (incubator) respectively. The vaccine samples were serially 
diluted. 100 µl of growth medium containing 10,000 cells were 
added to all the wells. 100 µl of maintenance medium was added to 
the control wells. 100 µl of serially diluted vaccine was added to 
each well except for the control. The plates were incubated in CO2 
incubator at 37°C for one week. This reading of potency was 
measured as 0th day potency. Similar tests were performed on 7th, 
14th, 21st, 28th and 35th day by incubating the vaccine kept at 2-8 ± 
0.5°C, 26 ± 0.5°C for  the  above  mentioned  periods.  The  vaccine  
 




Table 1. Growth of RD cells vs. serum concentration of GM. 
 
Expt No. Concentrations of serum Cell count millions/ml 
1 6% 3.843 
2 8% 4.623 
3 10% 4.80 
4 12% 5.112 
5 14% 6.540 
 










sample that is kept at 37 ± 0.5°C was tested for potency on the 3rd, 
5th and 7th day. The potency of the vaccine was calculated using 
Karber’s Formula: 
 
Negative log of TCID50 endpoint = N-[(S/100 - 0.5) x log of dilution] 
 
Where N = negative log of highest virus concentration used, and S 





The effect of varying serum concentration in the growth 
media was studied with respect to the growth of RD cell 
line. The cell growth was known to increase with serum 
concentration. The values for cell count are presented in 
Table 1 and Figure 1. 
Different volumes of the media were studied with 
respect to their effect on RD cell growth after observing 
for three days. Complete monolayer was formed on the 
day of observation. The values for cell count are presen-
ted in Table 2 and Figure 2. 
Thus the growth medium containing 10% serum con-
centration and 10 ml volume of media was selected for 
the growth of RD cells as the monolayer formation was 
convenient for the study to be carried on testing the 
potency of vaccine. 
The potency of the given vaccine samples A and B 
were tested by incubating at three different temperatures. 
The samples were kept at 26 ± 0.5°C, 2-8 ± 0.5°C, and 
37 ± 0.5°C for various periods of incubation. 
Infectivity titre method was employed to find out the 
drop in potency of the samples, the potency drop was 
checked periodically in specific intervals, the culture 
which was incubated with vaccines would show cyto-
pathic effect after a certain period of  incubation, the 
cultures showing cytopathic effect was counted and 





The initial titre was 6.93 log TCID50 and the samples 
which were exposed to 2-8 ± 0.5°C started declining after  
 




Table 2. Growth of RD cells at different volumes of media. 
 
Expt No. Volume of Media Initial pH Final pH Cell Count* 
1 8 ml 7.8 7.06 2.050 
2 9 ml 7.8 7.16 2.600 
3 10 ml 7.8 7.60 4.300 
4 11 ml 7.8 7.90 5.100 
5 12 ml 7.8 7.70 6.450 
 










Table 3. Virus titre at 26 ± 0.5°C. 
 
Expt No. Temperature Days Sample A* Sample B* 
1. -20°C 0th -6.82 -6.88 
2. +26°C 7th -5.90 -6.01 
3. +26°C 14th -5.1 -5.3 
4. +26°C 21st -4.5 -4.6 
5. +26°C 28th -4.0 -4.11 
6. +26°C 35th -3.2 -3.4 
 
*The values of sample A, sample B are expressed as the negative log of TCID50 of 




seven days. A drop of 0.33 log TCID50 was noticed from 
7th day and further drop of 0.53 log TCID50 was noticed 
on the 14th day. Since the initial vaccine titre was more 
than the requirement, the vaccine was able to pass the 
minimum requirement in spite of 0.5 log drop. But at 21st, 
28th, 35th day, the drop was more than the 0.5 log. Hence 
the vaccine failed to comply with the minimum require-
ment. In the case of the samples being exposed to 26 ± 
0.5°C, the drop in titre was noticed on the 7th day and the 
titre was below the minimum requirement. In the case of 
the samples being exposed to 37 ± 0.5°C, the drop in titre 
was significant within 24 h and by the second day the 
virus titre was below the minimum requirement. The 
values   are  presented  in  the  Tables  3,  4  and  5,  and  
 




Table 4. Virus titre at 2-8 ± 0.5°C. 
 
Expt. No. Temperature Days Sample A* Sample B* 
1. -20°C 0th -6.93 -6.85 
2. 2-8°C 7th -6.60 -6.5 
3. 2-8°C 14th -6.43 -6.33 
4. 2-8°C 21st -6.1 -6.17 
5. 2-8°C 28th -5.8 -5.9 
6. 2-8°C 35th -5.4 -5.5 
 
*The values of sample A, sample B are expressed as the negative log of TCID50 




Table 5. Virus titre at 37 ± 0.5°C. 
 
Expt. No. Temperature Days Sample A* Sample B* 
1. -20°C 0th -6.63 -6.69 
2. +37°C 1st -6.43 -5.93 
3. +37°C 2nd -5.93 -5.75 
4. +37°C 3rd -5.62 -5.50 
5. +37°C 4th -5.50 -5.37 
6. +37°C 5th -5.36 -5.21 
 
*The values of sample A, sample B are expressed as the negative log of TCID50 of the 















The initial  titre  was  6.85  log  TCID50  and  the  samples  
which were exposed to 2-8 ± 0.5°C started declining after 
7 days. A drop of 0.35 log TCID50 was noticed from 7
th 
day and further drop of 0.52 log TCID50 was noticed on 
the 14th day. Since the initial vaccine titre was more than 
the requirement, the vaccine was able to pass the mini-
mum requirement in spite of 0.5 log drop. In  the  case  of  
 
















the samples being exposed to 26 ± 0.5°C, the drop in titre 
was noticed on the 7th day, a drop of 0.87 log TCID50 was 
noticed. Since the vaccine titre was not more than the 
minimum requirement, the vaccine was not able to pass 
the minimum requirement in spite of 0.5 log drop. In the 
case of the samples being exposed to 37 ± 0.5°C, the 
drop in titre was noticed within 24 h and there was a drop 
of 0.86 log TCID50 on the seventh day. Further drop of 
1.32 log TCID50 was noticed at 4
th day. The vaccine titre 
was below the minimum requirement. The values are 





Growth of RD cells vs. serum concentration of GM 
 
8%  serum   concentration  supported  the  growth  of  RD  
 




cells in the same way as that of 10 and 6% serum con-
centration showed a poor cell count. The cell growth was 
known to increase with serum concentration, but in the 
case of 12 and 14%, confluent monolayer was formed on 
the second day itself. The cells detached from the 
surface on the third day that resulted in decreased avail-
ability of cells for the potency test. Therefore 10% serum 
concentration was selected for the growth of RD cells that 
were used for testing the potency of vaccine. 
 
 
Growth of RD cells at different volumes of media 
 
The normal volume of media used for the growth of RD 
cells is 10 ml. Varying volumes of the media were studied 
with respect to their effect on RD cell growth after 
observing for three days. 10, 11 and 12 ml, of the growth 
media imparted effective growth on RD cells as 
evidenced by high cell count, whereas 8 and 9 ml of the 
media showed poor cell count when compared with other 
volumes of media under study. 10 ml of the growth me-
dium was selected for the growth of RD cells as the 
amount was affordable, monolayer formation and cell 




Potency drop at various temperatures 
 
The fall in infectivity is due to the hydrolysis of the geno-
mic RNA by the RNA polymerase within the virus particle. 
This can be greatly inhibited by the suppression of the 
enzymatic activity which can be achieved by reducing the 
pH below 7 (Newman et al., 1995). 
 
 
Potency drop at 26 ± 0.5°C 
 
At 26 ± 0.5°C the vaccine potency was found out to be -
6.82 for Sample A and -6.88 for Sample B and the 
potency drops according to the duration of exposure to 
the temperature. After 7 days of incubation the potency 
dropped to a value of -5.9 and -6.01 for Sample A and 
Sample B respectively. At 22°C the average loss in virus 
titre after 21 days was about 1.50 (Sokhey et al., 1988). 
In a study conducted previously whereas in our study the 
average loss in virus titre after 21 days at 26 ± 0.5°C was 
about 2.30. Thus proving that the potency drops as the 
temperature of incubation of the vaccine increases.  
 
 
Potency drop at 2-8 ± 0.5°C 
 
The vaccine that was incubated in 2-8 ± 0.5°C shows a 
lesser amount of potency drop like that of another study 
where not much loss in virus titre in three samples stored 





et al., 1988). The average loss in virus titre in a year (log 
TCID50) was 0.65 at 4 - 8°C when various samples were 
stored at these whereas in our study 0.5 log drop was 
observed at the 14th day of incubation itself.  
 
 
Potency drop at 37 ± 0.5°C 
 
The drop in potency of the vaccine kept at 37 ± 0.5°C 
was rapid. The vaccine showed a good margin of potency 
loss after 5 days of incubation. The initial potency has 
been calculated and it is -6.63 and -6.69 for the Samples 
A and B respectively. After the incubation of 5 days in 37 
± 0.5°C potency was found to be -5.36 and -5.21 for 
Sample A and Sample B respectively in the same way as 
that of a study conducted earlier where the samples 
exposed to 36°C for 21 days showed almost complete 





The expanded programme of immunization (EPI) was 
launched globally in 1978 and it targeted on six childhood 
diseases, which includes poliomyelitis. In India universal 
immunization programme was launched in 1985, prior to 
1997, surveillance for polio was directed at finding clinical 
polio cases by passive reporting from health facilities. 
The number of polio cases in India has dropped from an 
estimated 32,630 in 1995, before the pulse polio 
programme began to just 268 in 2001. The number of 
polio cases associated with isolation of wild poliovirus 
decreased from 1934 in 1998, 1126 in 1999, 265 in 2000 
and 268 in 2001. Polio has disappeared from large parts 
of country. By the end of 2001 most of India was either 
polio free or in a good position to achieve that status 
shortly thereafter (AFP alert NPSP, 2001). 
Studies have been undertaken as poliovirus is 
thermolabile which requires continuous monitoring of cold 
chain. Exposure of these viruses to higher temperature 
destroys them rapidly and makes the vaccine unusable. 
Since there is a close relationship between storage 
temperature and poliovirus survival, manufacturers re-
commend expiry dates for OPV according to the tempe-
rature at which it is kept. Many give two figures: (1) Up to 
two years if the vaccine is stored in a deep freezer at or 
below -20°C; and (2) for six months if it is stored in a 
refrigerator at 0-8°C. One manufacturer stated that 
magnesium chloride-stabilized vaccine maintains ade-
quate immunogenicity for 12 months when kept in a 
refrigerator at 2 - 8°C, for three weeks at 25°C, and for 
three days at 37°C. 
Our study clearly showed that the live attenuated polio 
vaccine does not retain its potency if the cold chain main-
tenance is not proper. Whenever the live polio vaccine is 
exposed to a temperature greater than freezing tempe-






vaccine seems to be directly proportional to the increase 
in temperature. The samples kept at -20°C retained full 
potency for the entire storage period and was used as 
control in this present study. The potency drop at 2 - 8°C 
after 35th day was 22.07% for Sample A and 19.70% for 
Sample B, the drop in potency for the vaccine kept at 
26°C after the 35th day was 53.07% for Sample A and 
50.14% for Sample B and the potency of vaccine 
decreased significantly as it was exposed to 37°C, the 
drop in potency for Sample A was 19.15% after the 5th 
day and for Sample B 22.12%. Previous studies show 
that Oral poliomyelitis vaccines may lose 4 - 13% of their 
activity per day at 25°C, 11 - 21% per day at 31°C and 26 
- 34% per day at 37°C. Poliomyelitis vaccines retained 
minimum potency for three days at 37°C and 14 to 21 
days at 25 - 28°C. 
The RD cells which were used for the study showed 
maximum growth in 14% fetal calf serum and when the 
serum concentration is fixed to 10%, it showed the maxi-
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